Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T | Zendy

Kase Adam M. | Zendy; KharfanDabaja Mohamed A. | Zendy; Donaldson Andrew | Zendy; Elliott Jamie | Zendy; Sher Taimur | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T

Author(s) -

Kase Adam M.,

KharfanDabaja Mohamed A.,

Donaldson Andrew,

Elliott Jamie,

Sher Taimur

Publication year - 2022

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.5572

Subject(s) - medicine , follicular lymphoma , lenalidomide , obinutuzumab , lymphoma , follicular phase , oncology , refractory (planetary science) , complete remission , rituximab , chemotherapy , multiple myeloma , physics , astrobiology

Patients with relapsed follicular lymphoma who do not respond to CAR‐T have a poor outcome. We present a case of refractory follicular lymphoma who relapsed after two CAR‐T infusions and achieved a complete remission after treatment with obinutuzumab and lenalidomide. This represents a promising treatment option in the post‐CAR‐T setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research